Passenger lymphocyte syndrome following organ and stem cell transplantation: current insights and clinical implications - Takeaways - MDSpire

Passenger lymphocyte syndrome following organ and stem cell transplantation: current insights and clinical implications

  • By

  • Zhong-yu Kang

  • Xue-ya Han

  • Chun Liu

  • Wei Liu

  • Dai-hong Li

  • June 11, 2026

  • 0 min

Share

  • 1

    Passenger lymphocyte syndrome (PLS) is an alloimmune complication of ABO-mismatched organ or stem cell transplantation.

  • 2

    PLS incidence varies by organ type, ranging from approximately 9% in kidney transplants to over 50% in lung transplants.

  • 3

    Most PLS cases present within 1–3 weeks post-transplant, often resulting in self-limiting hemolysis.

  • 4

    Diagnosis of PLS is challenging due to symptom overlap with acute rejection and other conditions, leading to underdiagnosis.

  • 5

    Standardized diagnostic criteria and evidence-based management strategies for PLS are needed to improve patient outcomes.

Original Source(s)

Passenger lymphocyte syndrome following organ and stem cell transplantation: current insights and clinical implications

  • by Zhong-yu Kang, Xue-ya Han, Chun Liu, Wei Liu, Dai-hong Li

  • June 11, 2026

Related Content

Secondary hemophagocytic lymphohistiocytosis in pediatric patients: a single-center experience

Early IL-1 inhibition and long-term remission in childhood-onset Still's disease: a real-world cohort study

Associated thromboembolic events to the post COVID syndrome: a systematic review and meta-analysis